Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Administration of Most Closely HLA-matched Multivirus-specific Cytotoxic T-Lymphocytes for the Treatment of EBV, CMV, Adenovirus, HHV6, and BK Virus Infections Post Allogeneic Stem Cell Transplant

NCT02108522 is registered in ClinicalTrials.gov with AlloVir as lead sponsor.

NCT NCT02108522
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02108522 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Administration of Most Closely HLA-matched Multivirus-specific Cytotoxic T-Lymphocytes for the Treatment of EBV, CMV, Adenovirus, HHV6, and BK Virus Infections Post Allogeneic Stem Cell Transplant
Lead sponsor
AlloVir
Phase
Not applicable
Overall status
Completed
Start date
June 30, 2014
Completion date
December 31, 2019
Enrollment
82 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

infection